ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: FR-OR088

An Autologous Cellularized In Vivo Engineered Vascular Graft Capable of Remodeling to a Non-Thrombogenic Blood Vessel upon Arteriovenous Grafting in Adult Goats

Session Information

Category: Dialysis

  • 704 Dialysis: Vascular Access


  • Geelhoed, Wouter, LUMC, Leiden, Netherlands
  • van der Bogt, Koen E.A., Haaglanden Medisch Centrum/LUMC, Den Haag, Netherlands
  • Rothuizen, Carolien, Leiden University Medical Center/Stafsecretariat Nephrology, Leiden, Netherlands
  • Hamming, Jaap, Leiden University Medical Center, Leiden, Netherlands
  • van Agen, Maarten Sebastiaan, Leiden University Medical Centre, The Hague, Netherlands
  • de Boer, Hetty C., Leiden University Medical Center, Leiden, Netherlands
  • Hinz, Boris, University of Toronto, Toronto, Ontario, Canada
  • Kislaya, Ankur, Delft University of Technology, Delft, Netherlands
  • Van Zonneveld, Anton Jan, Leiden University Medical Center, Leiden, Netherlands
  • Rabelink, Ton J., LUMC, Leiden, Netherlands
  • Moroni, Lorenzo, Maastricht University, Maastricht, Netherlands
  • Rotmans, Joris I., LUMC, Leiden, Netherlands

The durability of prosthetic vascular grafts used for hemodialysis access is poor due to venous stenosis, limiting vascular access. We present a method to create tissue engineered blood vessels (TEBVs) capable of developing in vivo towards a functional vascular graft.


Polymeric rods are implanted subcutaneously in goats for 1 month, resulting in the formation of fibrocellular tissue capsules (TC’s) with sufficient mechanical strength to restrain arterial pressure. The TC’s then are grafted as arteriovenous conduit between the carotid artery and jugular vein. After 1 or 2 months in the vasculature the grafts were harvested.


Ex vivo perfusion showed grafts were less thrombogenic than initial TCs, and also when compared to ePTFE grafts. At 1 month the TEBVs were composed of vascular smooth muscle cell-like cells, with confirmed contractility. At 2 months, complete endothelialisation and elastin formation was also observed, while in vivo graft patency was comparable to ePTFE.


Here, we demonstrate the in vivo remodelling capacity of TC into TEBV, and their potential as replacements for prosthetic vascular grafts.